Informação da revista
Vol. 42. Núm. 3.
Páginas 287-290 (Março 2023)
Partilhar
Partilhar
Baixar PDF
Mais opções do artigo
Visitas
1040
Vol. 42. Núm. 3.
Páginas 287-290 (Março 2023)
Research Letter
Open Access
Role of exercise echocardiography in paradoxical low gradient severe aortic stenosis
Papel da ecocardiografia de sobrecarga na estenose aórtica grave de gradiente baixo paradoxal
Visitas
1040
Jesús Peteiro
Autor para correspondência
pete@canalejo.org

Corresponding author.
, Lucia Valmisa, Alberto Bouzas-Mosquera
Laboratory of Stress Echocardiography, Department of Cardiology, Complejo Hospitalario Universitario de A Coruña (CHUAC), University of A Coruña, CIBER-CV, A Coruña, Spain
Este item recebeu

Under a Creative Commons license
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (1)
Texto Completo

Aortic stenosis (AS) with a valve area (AVA) <1 cm2 but mean gradient (MG) <40 mmHg in the presence of normal ejection fraction (LVEF ≥50) is a matter of concern, when considering the true severity of AS.1,2 We hypothesized that exercise echocardiography (ExE) could offer additional information by two pathways: the detection of LV systolic dysfunction and changes in AV hemodynamics.

Consecutive asymptomatic, or low symptomatic/equivocal symptoms patients with paradoxical low gradient (LG) severe AS were studied. We measured AVA, maximum and MG, mitral regurgitation (MR), systolic pulmonary artery pressure (sPAP) and LV early filling/early mitral annulus septal systolic movement (E/e′) ratio3 (EPIC 7, Philips). Moderate MR was considered significant.

Patients underwent a treadmill ExE (Bruce protocol 76%).4,5 Peak imaging assessed LV systolic function (global, regional) and post-exercise the rest of measurements (MR, E/e′, AVA, gradients, sPAP). The study was approved by our Ethics Committee. End points were all-cause mortality, nonfatal MI, admittance for unstable coronary syndrome or for cardiac failure, or symptomatic progression leading to AV replacement and/or coronary revascularization.

Table 1 shows clinical characteristics and ExE data; low-flow LG-AS was observed in 17 patients (38%), and normal-flow LG (>/=35 ml/m2) in 28 (62%). AVA at exercise was evaluated in 33 subjects, as bad tracing quality/technical reasons prevented assessment in 12. Findings of moderate AS at exercise (AVA ≥1 cm2 plus MG <40 mmHg) were observed in 10/33 (30%) patients and of definitively severe AS (AVA <1 cm2; MG ≥40 mmHg) in 7/33 (21%), with no differences in % between low-flow and normal flow. AVA and MG at rest were worse in patients with definitively severe AS in exercise (p<0.05 both) and increase in blood pressure lower (p=0.08). Angiography performed in 32 patients showed coronary artery disease (CAD) in 15 (exercise WMAs in nine) and was normal in 17 (exercise wall motion abnormalities [WMAs] in three).

Table 1.

Clinical characteristics in the overall group; and resting and exercise echocardiography data, and changes with exercise in subgroups (low-flow low gradient and normal-flow low-gradient AS).

Clinical characteristics
Age, y  74±12 
Female gender, n (%)  32 (71) 
Diabetes, n (%)  13 (29) 
Hypertension, n (%)  33 (73) 
Hypercholesterolemia (51%)  23 (51) 
Atrial fibrillation, n (%)  9 (20) 
History of CAD, n (%)  13 (29) 
Calcium channel blockers, n (%)  10 (22) 
Nitrates, n (%)  6 (13) 
AECI/ARAs, n (%)  20 (44) 
Digoxin, n (%)  1 (2) 
Diuretics, n (%)  7 (16) 
Betablockers, at the time of the ExE, n (%)  7 (16) 
Symptoms, n (%)
Asymptomatic  16 (36) 
Chest pain  10 (22) 
Equivocal/low grade dyspnea  12 (27) 
Any chest pain plus equivocal dyspnea  7 (15) 
Resting echocardiography
Myocardial thickness, mm  12.3±2.4 
Global LV longitudinal strain  −19.3±4.0 
Calcium score2*  15 (34) 
Resting WMAs  3 (7) 
Exercise echo data    p values intergroup (rest, exercise) 
>85% of the age-predicted maximum heart rate, n (%)  37 (82)  NS
LFLG  16 (94) 
NFLG  21 (75) 
Achieved METs  6.6±2.2  NS
LFLG  6.2±2.2 
NFLG  6.7±2.1 
Symptoms with exercise, n (%)  14 (31)  NS
LFLG  4 (24) 
NFLG  10 (36) 
Blunted blood pressure response, n (%)  17 (38)  NS
LFLG  4 (24) 
NFLG  13 (46) 
Ischemia, n (%)  15 (33)   
LFLG  4 (24)  NS 
NFLG  11 (39)   
Changes from rest to exercise  Rest  Exercise   
Heart rate (bpm)  79±18  139±20   
LFLG  89±19  145±24  Rest NS 
NFLG  73±14  135±16  Ex. NS 
Blood pressure (mmHg)  136±28  164±31   
LFLG  135±31  170±28  Rest NS 
NFLG  137±26  160±32  Ex. NS 
LV ejection fraction (%)  61±7  64±8   
LFLG  57±5  64±10  Rest 0.001 
NFLG  63±6  64±8  Ex. NS 
Wall motion score index  1.03±0.15  1.13±0.24   
LFLG  1.06±0.24  1.17±0.33  Rest NS 
NFLG  1.00±0.03  1.10±0.16  Ex. NS 
Aortic valve area, cm2  0.84±0.16  0.95±0.25   
LFLG  0.81±0.19  0.86±0.14  Rest NS 
NFLG  0.85±0.23  1.00±0.25  Ex. 0.06 
Mean aortic gradient (mmHg)  27±7  35±9   
LFLG  25±8  34±11  Rest 0.08 
NFLG  28±6  35±7  Ex. NS 
Maximal aortic gradient (mmHg)  51±12  68±19   
LFLG  48±15  63±23  Rest NS 
NFLG  52±10  71±15  Ex. NS 
Systolic pulmonary artery pressure, mmHg (n)  42±13 (23)  56±18 (21)   
LFLG  42±13  54±17  Rest NS 
NFLG  42±14  58±13  Ex. NS 
E/e′>15 and/or restrictive pattern  17 (38)  18 (40)   
LFLG  8 (47)  7 (41)  Rest NS 
NFLG  9 (32)  11 (39)  Ex. NS 
Moderate or severe MR, n (%)  4 (9)  3 (7)   
LFLG  1 (6)  1 (6)  Rest NS 
NFLG  3 (11)  2 (8)  Ex. NS 

METs depicts metabolic equivalents; ACEI: angiotensin converting enzyme inhibitors; ARAs: angiotensin receptor antagonists; LFLG: low-flow low-gradient aortic stenosis; NF: normal flow; Ex.: exercise.

*

The aortic valve calcium score was semi-quantitatively measured by echocardiography, scoring small area of calcification as 1, moderate extension affecting 1–2 valves as 2, and extensive calcification affecting 2–3 valves as 3; ExE: exercise echocardiography; MR: mitral regurgitation; WMAs: wall motion abnormalities.

During follow-up of 22±18 months, there were 29 events. Resting wall motion score index (WMSI), metabolic equivalents, left ventricular ejection fraction and WMSI at exercise, Δ WMSI, abnormal ExE, significant MR at exercise, and digoxin were associated with events. Independent predictors were digoxin (HR=44.8, p=0.003), resting WMSI (HR=87.5, p=0.001), Δ in WMSI (HR=11.3, p=0.002), and significant exercise MR (HR=6.1, p=0.006). Figure 1 shows Kaplan-Meier curves according to ExE results, and an example of moderate AS performance at exercise.

Figure 1.

(A) Event-free survival Kaplan-Meier curves for patients with normal and abnormal exercise echocardiography findings. (B) Example of a patient with low-gradient severe AS, that developed hemodynamic data of moderate AS with exercise. Arrows: lateral ischemia. Post-test angiography demonstrated CAD.

(0,31MB).

To our knowledge, this is the first study investigating treadmill ExE for defining outcomes in LG-AS. The main findings were that ExE was useful to detect outcome mainly by demonstrating exercise WMAs but failed in exploring the benefit of AV hemodynamics. Our data emphasize that in this scenario, it is not just the AV disease that matters, but that CAD is commonly associated and can affect the outcome.

One study employed dobutamine stress or supine bicycle in paradoxical LG-LF AS,6 finding greater severity with stress (smaller AVA, smaller projected AVA, and higher gradients) in patients in whom the anatomical extracted AV during surgery showed greater severity. Also, they observed that projected AVA was an independent predictor of outcome. Hence, exercise could be of interest for assessing outcome, suggesting that lower gradients during exercise, and greater AVA would be data of less severe outcome, therefore, reclassifying these patients.

Some of our patients had findings of non-severe AS such as limited hypertrophy and AV calcification, and moderate AS at exercise. On the other hand, symptom explanations can come from diastolic dysfunction, as well as from the aforementioned associated ischemic CAD. Although our research failed to find any association between exercise hemodynamics and outcome, we would like to encourage others to further look for insights into LG-AS. However, an ExE for assessing ischemia can offer prognostic information on these subjects.

Limitations included the small sample that prevented the study of certain relationships, such as those derived from assessment of AV parameters. AVA at exercise was not assessed in all patients; and ExE results were available to the responsible clinicians.

Authors’ contributions

All authors have read and approved the manuscript. It has not been published and is not being considered for publication elsewhere. Jesús Peteiro and Alberto Bouzas-Mosquera participated in the design, data acquisition, and data analysis, whereas Lucia Valmisa revised it critically and gave final approval.

Funding

This work was supported by the Spanish Society of Cardiology (Project of Clinical Research in Cardiology Dr. Pedro Zarco 2017).

Conflict of interest

There is no conflict of interest to disclose.

References
[1]
P. Lancellotti, J. Magne, E. Donal, et al.
Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification.
J Am Coll Cardiol, 59 (2012), pp. 235-243
[2]
L. Galian-Gay, R.A. Escalona-Silva, G. Teixidó-Turà, et al.
Prognosis of paradoxical low-flow low-gradient aortic stenosis: a severe, non-critical form with surgical treatment benefits.
Front Cardiovasc Med, 9 (2022), pp. 852954
[3]
A. Vahanian, F. Beyersdorf, F. Praz, et al.
Guidelines for the management of valvular heart disease.
Eur Heart J, 43 (2022), pp. 561-632
[5]
J. Peteiro, A. Bouzas-Mosquera, C. Barbeito-Caamaño, et al.
Additive prognostic and diagnostic value of diastolic exercise parameters in patients referred for exercise echocardiography.
Eur Heart J Cardiovasc Imaging, 24 (2022), pp. 108-118
[6]
M.A. Clavel, P.V. Ennezat, S. Maréchaux, et al.
Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF.
JACC Cardiovasc Imaging, 6 (2013), pp. 175-183
Copyright © 2023. Sociedade Portuguesa de Cardiologia
Idiomas
Revista Portuguesa de Cardiologia
Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.